Analyst Downgrades: Tetraphase Pharmaceuticals Inc, Flexion Therapeutics Inc, and MannKind Corporation

Analysts downwardly revised their ratings and price targets on Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH), Flexion Therapeutics Inc (NASDAQ:FLXN), and MannKind Corporation (NASDAQ:MNKD)

by Josh Selway

Published on Sep 9, 2015 at 10:03 AM

Analysts are weighing in on drugmakers Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)Flexion Therapeutics Inc (NASDAQ:FLXN), and MannKind Corporation (NASDAQ:MNKD). Here's a quick roundup of today's bearish brokerage notes on TTPH, FLXN, and MNKD.

  • Unlike another of its drugmaker peersTTPH is having a disastrous morning. The shares have plummeted 79% to $9.40 -- and panned an annual low of $9 -- after the company announced its experimental bowel drug failed in a late-stage study. The bearish brokerage notes have since poured in, with Nomura, for one, cutting the stock's rating to "neutral" from "buy," while slashing its price target to $10 from $54. Before today, Tetraphase Pharmaceuticals Inc had easily doubled on the charts during the past 12 months -- helping to explain why 100% of covering analysts considered the shares worthy of a "buy" or better endorsement -- but now finds itself in territory not seen since May 2014. 

  • FLXN is suffering a similar fate this morning, with the shares sliding 30.4% after the company revealed its experimental pain drug failed in a mid-stage study. Short sellers are likely pleased with this news, however; specifically, short interest shot 42.2% higher during the most recent two-week reporting period. Now, it would take these bears almost seven days to repurchase their shares, at Flexion Therapeutics Inc's average daily trading pace. With FLEX trading at $20.18, it's now sitting 46.3% below its consensus 12-month price target of $37.60. Needham, though, just trimmed its price target on the equity to $28 from $31.

  • Finally, MNKD is down 7.5% at $3.77, following a downgrade to "underweight" from "neutral," and a price-target cut to $1.50 from $4, at Piper Jaffray. In its note, the brokerage firm stated MannKind Corporation has "vastly over-estimated" the potential of its diabetes drug Afrezza. Despite historically outperforming in September, the stock has barely budged on a month-to-date basis. Longer term, MNKD has underperformed the S&P 500 Index (SPX) by 29.4 percentage points during the past 60 sessions. As such, short sellers have been piling on, with 45.6% of the stock's float sold short -- or 21.6 times the average daily trading level.
Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.
Patent Lawsuit Loss Sends AMRN Stock Spiraling
Amarin just lost a major U.S. patent lawsuit for its heart drug Vascepa
RH Stock Sinks Despite Earnings Beat
J.P. Morgan Securities and Cowen and Company cut their price targets
The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.